Hologic, Inc.
Hologic is a global leader in women's health, dedicated to innovation in medical diagnostics, breast health, gynecological minimally invasive surgery, and skeletal health. With a mission to provide precise, early, and accurate results, Hologic aims to improve health outcomes for women worldwide through advanced technology and comprehensive solutions. The company emphasizes research, clinical excellence, and a commitment to societal well-being, including sustainability and philanthropy.
Industries
Nr. of Employees
Very Large (1000+)
Patents
System and method for navigating a tomosynthesis stack using synthesized image data
US-12307604-B2
View Details
System and method for navigating a tomosynthesis stack using synthesized image data
US-12307604-B2
View DetailsProducts
Liquid‑based cytology preservation solution
Specimen preservation reagent for cervical cytology enabling liquid-based sample collection and downstream automated processing.
Automated liquid‑based cytology processors
Laboratory instruments for automated slide preparation and liquid‑based cytology sample processing.
Automated nucleic acid testing platform
Random‑access molecular diagnostics system providing continuous processing and automation for high-throughput NAAT assays.
Multiplex molecular diagnostic assays
Nucleic-acid assays for detection and quantitation of viral infections and vaginitis pathogens from single specimens.
Digital cytology slide imaging and AI‑assisted diagnostics
Systems for digitising glass slides and applying algorithmic analysis to prioritise and flag relevant cellular images for reviewer assessment.
Digital mammography and tomosynthesis systems
2D digital mammography and 3D tomosynthesis imaging systems for breast cancer screening and diagnostic workflows.
Liquid‑based cytology preservation solution
Specimen preservation reagent for cervical cytology enabling liquid-based sample collection and downstream automated processing.
Automated liquid‑based cytology processors
Laboratory instruments for automated slide preparation and liquid‑based cytology sample processing.
Automated nucleic acid testing platform
Random‑access molecular diagnostics system providing continuous processing and automation for high-throughput NAAT assays.
Multiplex molecular diagnostic assays
Nucleic-acid assays for detection and quantitation of viral infections and vaginitis pathogens from single specimens.
Digital cytology slide imaging and AI‑assisted diagnostics
Systems for digitising glass slides and applying algorithmic analysis to prioritise and flag relevant cellular images for reviewer assessment.
Digital mammography and tomosynthesis systems
2D digital mammography and 3D tomosynthesis imaging systems for breast cancer screening and diagnostic workflows.
Services
Delivery and coordination of training programs and certified training bases for cervical cytology and tissue pathology in collaboration with national medical associations.
Collaboration with public health organisations to supply reagents, support screening campaigns and run awareness/education initiatives for cervical and breast cancer screening.
Delivery and coordination of training programs and certified training bases for cervical cytology and tissue pathology in collaboration with national medical associations.
Collaboration with public health organisations to supply reagents, support screening campaigns and run awareness/education initiatives for cervical and breast cancer screening.
Expertise Areas
- Cervical cancer screening and cytology
- Molecular diagnostics and multiplex NAAT
- Breast imaging and tomosynthesis
- Minimally invasive gynecologic surgery
Key Technologies
- Liquid-based cytology
- Digital cytology and whole‑slide imaging
- AI-based image analysis
- Random-access automated molecular platforms
News & Updates
The Genius Digital Diagnostics System received CE mark in 2021 and FDA clearance in 2024, enabling rapid, AI-assisted cervical cancer screening with over six million women screened worldwide.
Research shows that digital breast tomosynthesis (DBT) significantly improves detection rates of invasive breast cancer, especially in women with dense breasts, and is poised to become a standard in screening guidelines.
Participation in World Breast Cancer Awareness Month
Hologic has been recognized for its contributions to women's health, including participation in annual breast cancer awareness campaigns and research.
Innovation in Imaging Technology
Development of advanced imaging systems like 3D mammography and tomosynthesis that enhance early detection of breast cancer.
The Genius Digital Diagnostics System received CE mark in 2021 and FDA clearance in 2024, enabling rapid, AI-assisted cervical cancer screening with over six million women screened worldwide.
Research shows that digital breast tomosynthesis (DBT) significantly improves detection rates of invasive breast cancer, especially in women with dense breasts, and is poised to become a standard in screening guidelines.
Participation in World Breast Cancer Awareness Month
Hologic has been recognized for its contributions to women's health, including participation in annual breast cancer awareness campaigns and research.
Innovation in Imaging Technology
Development of advanced imaging systems like 3D mammography and tomosynthesis that enhance early detection of breast cancer.